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Rapid oxygen-dependent changes in erythropoietin mRNA in perfused
rat kidneys: Evidence against mediation by cAMP. Erythropoietin (EPO)
is mainly produced in the kidneys and is regulated by blood oxygen
availability. Studies with isolated perfused kidneys have established
that an oxygen-sensing system exists intrarenally but the mechanisms
involved are poorly understood. Using a quantitative RNase protection
assay, we have demonstrated oxygen-dependent EPO mRNA produc-
tion in isolated perfused rat kidneys, with EPO mRNA levels increasing
30-fold when perfusate p02 was reduced from 474 to 25 mm Hg. To
determine if the high amplitude changes in EPO mRNA levels in
response to hypoxia are mediated by cyclic AMP, four agents, which
activate the cyclic AMP system in different ways, were administered to
isolated kidneys perfused over a range of perfusate P°2. Salbutamol
and N6-ethyl carboxamidoadenosine, which activate adenylate cyclase,
dibutyryl cyclic AMP (a cyclic AMP analogue) and forskolin did not
augment EPO mRNA production, and no significant differences in the
regression of log (EPO mRNA) on perfusate P°2, were found between
experimental groups exposed to each of these compounds and controls.
We conclude that the rapid increase in EPO mRNA levels in response
to hypoxia is not mediated or substantially modulated by a cyclic
AMP-dependent mechanism.
Erythropoietin (EPO) is the primary hormone controlling
erythrocyte production. Recognition that a major control of
EPO production operates through rapid, high amplitude
changes in the level of EPO mRNA in response to tissue
oxygenation [1] has led to particular interest in EPO regulation
as an important example of oxygen-dependent gene expression.
The cyclic AMP (cAMP) system is one of the best understood
cellular signalling mechanisms which may transduce an external
stimulus to modulate gene transcription. In addition, alteration
of EPO production by agents which interact with the cAMP
system in a variety of models has raised the possibility that
cAMP may be an important mediator in the mechanism of
oxygen sensing [2—11]. Early experiments established a tempo-
ral relationship between changes in renal cAMP levels, follow-
ing exposure of animals to hypoxia or cobalt chloride, and
increases in serum EPO concentration [2, 3], and that adminis-
tration of cAMP [4, 5], or its analogues [2, 4, 5], to whole
animals stimulated EPO hormone production in vivo. Further
work showed that the administration of adenosine A2 receptor
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agonists [6] and /32-adrenergic agonists [71, which activate
adenylate cyclase, also resulted in increased EPO production in
ex-hypoxic polycythaemic mice, and in "programmed" iso-
lated perfused dog kidneys [8, 9].
In contrast to these observations, Ueno et at [12], using a
hepatoma cell line HepG2, were unable to demonstrate any
significant rise in intracellular cAMP levels after exposure to
hypoxia, although EPO concentrations in the culture medium
increased fourfold, under these conditions. Furthermore, they
found that forskolin and cholera toxin did not increase EPO
hormone production under normoxic conditions, but had an
additive effect with hypoxia, raising the possibility that the
modulatory role of cAMP was in amplifying the EPO response
to hypoxia. Further conflicting data were provided by Scholz
and co-workers [131 who found that forskolin did not have any
effect on EPO hormone production in isolated kidneys, from
normoxic rats, perfused under both well-oxygenated and hy-
poxic conditions. In contrast, studies using human renal cell
carcinoma cell lines, showed that the administration of cAMP
analogues stimulated EPO production under both normoxic [10]
and hyperoxic conditions [11]. These discrepancies might have
arisen because complex interactions in vivo allow the possibil-
ity of indirect effects on oxygen-sensing, for instance through
systemic hemodynamic actions. Alternatively, EPO production
by cells in culture might be dependent on factors which are not
rate limiting in vivo.
We have developed an RNase protection assay to study
modulation of EPO mRNA in isolated perfused rat kidneys.
During two hours of isolated perfusion, increases in EPO
mRNA of up to 30-fold were observed, which are of comparable
magnitude to the renal EPO mRNA response to two hours of
hypoxic stimulation in vivo (unpublished observations), indi-
cating that the key steps in hypoxic sensing are preserved in this
model. We argued that if cAMP was an important mediator in
this system, then it should be possible to achieve large alter-
ations in the modulation of EPO mRNA by application of
substances which interact with cAMP metabolism. We have
therefore studied the action of four compounds which operate
on the cAMP system in different ways. Dibutyryl cyclic AMP
(dbcAMP), forskolin, salbutamol (a /3-2 adrenergic agonist) and
N6-ethyl carboxamidoadenosine (NECA, an adenosine A2 re-
ceptor agonist) were administered to isolated rat kidneys, and
perfused under conditions in which oxygen-dependent modula-
tion of EPO mRNA could be demonstrated.
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Methods
Kidney perfusion
Male Wistar rats weighing 350 to 375 g were used in all
experiments. Under intraperitoneal pentobarbital anaesthesia
(60 mg/kg), the right kidney was exposed, and cannulation of
the ureter, inferior vena cava (IVC) and right renal artery were
performed using modifications of the method described by
Nishiitsutsuji-Uwo et al [14]. The cannulated kidney was per-
fused in a recirculating circuit for two hours. The perfusate
comprised Krebs-Henseleit buffer containing 3 g/l00 ml bovine
serum albumin (Fraction V, Miles Laboratories, Slough, UK),
with glucose (5 mmol/liter) and the 20 physiological amino acids
[151, and was supplemented with washed human erythrocytes
to achieve a final hematocrit of 10%. As previous work with this
model has shown that changes in perfusion flow rate have a
profound effect on EPO mRNA production [16], all experiments
in this study were performed at a constant flow rate of 12
mllmin, which was monitored using an in-line rotameter (Meter-
ate, Herts, UK) calibrated at the beginning of each experiment.
'4C-inulin (Amersham International, Amersham, UK) was
added at the start of each perfusion and levels were measured,
at 30, 60, 90 and 115 minutes, in samples of perfusion medium
and in ten-minute urine collections. Urine and plasma sodium
concentrations were measured by flame photometry (Instru-
mentation Lab., UK). The perfusion media were gassed with
mixtures of 95% 02-5% C02, 95% air-5% C02, or 95% N2-5%
CO2 in varying proportions to achieve the desired perfusate
pAO2 for each experiment. For the measurement of venous and
arterial oxygen tension, gas-tight glass syringes (Hamilton
Company, Nevada, USA) were used to collect samples of
medium from the IVC cannula and from a sell-sealing silicon
port mounted onto the top of the renal arterial cannula. Oxygen
tensions were measured using an ABL-2 blood gas analyser
(Radiometer, Copenhagen). The hemoglobin-bound oxygen
content (mol/liter) was calculated from the formula: 0.62 x
saturation (fractional) x hemoglobin concentration (g/dl). The
dissolved oxygen content of the perfusate was calculated ac-
cording to the formula: 02 content (mol/liter) = 1.257 x l0
X [p02(mm Hg) x (1-hematocrit)] [17]. Renal oxygen consump-
tion was derived from these calculations. Since the right kidney
was homogenized after perfusion, oxygen consumption was
expressed per gram of the left kidney wet weight.
Experimental procedures
Control experiments. Eleven control experiments were per-
formed under identical conditions except that the gas mixtures
used were altered to achieve a different perfusate pAO2 for each"
experiment, ranging from approximately 25 to 500 mm Hg.10 Experiments with dbcAMP, forskolin, NECA and salbuta-
mol. Stock solutions of dbcAMP and salbutamol (Sigma Chem-
ical Company, Poole, UK), were made by dissolving the
compounds in phosphate-buffered saline on the day of use.
Similarly, stock solutions of forskolin and NECA (Sigma Chem-
ical Company) were made in absolute ethanol.
For each experiment, the perfused kidney was allowed to
stabilize for 15 minutes, after which arterial and venous samples
of perfusate were taken for measurements of oxygen tension,
and the agent added to achieve the appropriate concentration.
Arterial and venous oxygen measurements were repeated after
a further 15 minutes and 75 minutes of perfusion.
For each agent, a series of five perfusions, with perfusate
pAO2 ranging from about 25 to 500 mm Hg, was performed. The
doses used were: Forskolin 10 tLM, NECA 1 frM and salbutamol
500 tg/liter. For dbcAMP, to account for metabolism by the
perfused kidney [181, an aliquot of the stock solution of the
agent was administered at 15 minutes of perfusion to achieve a
perfusate concentration of 100 ,sM, and a further 50% of this
dose repeated 60 minutes later. The concentrations of forskolin
and salbutamol used have previously been reported to stimulate
EPO hormone production [8, 9, 12, 19]. Forskolin and NECA,
at the stated concentrations, have been shown to substantially
increase renin production in isolated perfused rat kidneys [20,
21], while the dose of dbcAMP used in this study has been
demonstrated to lead to significant and sustained activation of
cAMP-dependent protein kinase in the same model [18].
Analysis of EPO mRNA
At the end of each perfusion, the kidney was homogenized in
guanidinium thiocyanate using a Polytron homogenizer oper-
ated at full power for one minute. RNA was purified on a
cesium chloride gradient and stored as an ethanol precipitate at
—80°C until analysis. RNA was also purified from contralateral,
non-perfused kidneys excised at the commencement of each
perfusion, to allow determination of basal EPO mRNA levels.
The RNase protection assay for EPO mRNA has been
previously described [16, 22]. Briefly, a Pst 1/Sac 1 fragment of
rat genomic DNA, containing 132 basepairs of exon V and 300
basepairs of the adjacent intron, was inserted into pSP64 to
serve as the template for generation of labelled EPO RNA
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Fig. 1. Duplicate assays of EPO mRNA and actin ruRNA. Duplicate
samples of total RNA purified separately from each of 12 kidneys
perfused for 2 hours under varying conditions of oxygenation, and from
each of the contralateral, non-perfused kidneys, were analyzed sepa-
rately. The plot of EPO mRNAlactin mRNA (x 10) from the duplicate
analyses demonstrate the reproducibility of the RNase protection
assay. r2 = 0.98 Pc 0.01.
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Table 1. Functional parameters (mean 1 su) of control kidneys after 30, 60, 90 and 115 minutes of perfusion
Parameters
Time minutes
30 60 90 115
Perfusion pressure mm Hg 58 14 52 9 52 8 57 12
GFR ,nl/min 0.61 0.31 0.71 0.40 0.62 0.33 0.57 0.31
FENa %
Perfusate p02> 150 mm Hg 3 1 2 1 2 1 2 I
Perfusatep0,<lSOmmHg 18 12 12±14 10±9
transcripts. Each RNase protection assay was internally con-
trolled by parallel hybridization with an actin riboprobe gener-
ated from a DNA template comprising an Ava 1/Hind III
fragment, encompassing the 76 basepair first exon and about
200 basepairs of adjoining sequence, inserted into pAM19.
Transcripts were continuously labelled with 32P-GTP (410 Ci!
mmol, Amersham International, Amersham, UK).
For the analysis of EPO mRNA, sample RNA was dissolved
in hybridization buffer (80% formamide, 40 mii PIPES, 400 mM
sodium chloride, 1 ms EDTA) and the RNA concentration
determined by absorbance measurements at 260 nM (DU 62
spectrophotometer, Beckman Instruments, Palo Alto, Califor-
nia, USA). 250 sg of total RNA was hybridized at 60°C with 0.5
to 1 x 106 cpm radiolabelled EPO probe. RNase digestion was
performed at 20°C for 30 minutes. A parallel hybridization of
each RNA sample with the actin probe was performed. As actin
mRNA is of i04 fold greater abundance in the kidney compared
with EPO mRNA, an aliquot of the original solution of sample
RNA, containing 2.5 g total RNA, was hybridized at 60°C with
1 to 2 x 106 cpm radiolabeled actin probe. After RNase
digestion, one-tenth of this hybridization was added to the
corresponding EPO hybridization so that the subsequent proc-
essing was performed together. RNase digestion was termi-
nated by addition of 60 diter proteinase K (1 mg/ml) with 3%
SDS. After phenol-chloroform extraction and ethanol precipi-
tation, the RNA was resuspended in 80% formamide dye and
electrophoresed in a denaturing 10% polyacrylamide gel. After
electrophoresis, the gels were dried, marker tags affixed to the
borders to allow subsequent alignment of the gel and X-ray film,
and autoradiography performed at —70°C. Quantitation of EPO
and actin mRNA levels was performed by counting the excised
bands from the gel in a flat bed liquid scintillation counter (1205,
Beta Plate, Pharmacia-Wallac OY, Turku, Finland). Actin
mRNA did not change in these experiments permitting its use as
an internal standard. Values obtained for the EPO mRNA
bands were divided by the counts for the corresponding actin
mRNA bands to determine the relative abundance of EPO
mRNA, referred to in this paper as the "EPO mRNA level."
Duplicate assays
Linearity and reproducibility of this assay have been previ-
ously reported [22]. To establish the reproducibility of the assay
for measurement of EPO and actin mRNA in perfused kidneys,
a series of 24 duplicate assays were performed. Homogenates
from each of 12 kidneys perfused for two hours under varying
conditions of oxygenation, and from each of the contralateral,
non-perfused kidneys, were divided into two aliquots, from
which total RNA was separately purified. RNA samples were
also analyzed separately and EPO mRNA and actin mRNA
levels quantified, as described.
Statistical analysis
Student's t-test was used to assess the statistical significance
of differences in means of variables. Since the relationship
between EPO mRNA levels and perfusate P°2 was logarithmic,
EPO mRNA levels were logarithmically transformed allowing
description of the relationship between log (EPO mRNA) and
perfusate P°2 by linear regression, and statistical comparison
by Student's t-test with Dunnett's correction for multiple com-
parisons with a control.
Results
Duplicate assays
The results of duplicate assays of EPO mRNA levels in
perfused and contralateral control kidneys are shown in Figure
1, which demonstrates the reproducibility of the RNase protec-
tion assay.
Controlperfusions
The functional parameters of the control kidneys, perfused
for two hours at 12 mLlmin, are shown in Table 1. Perfusion
pressure, glomerular filtration rate and renal oxygen consump-
tion remained relatively unchanged throughout the course of
each perfusion, reflecting the functional stability of the prepa-
rations. The fractional excretion of sodium (FENa) was less
than 5% in the kidneys perfused under well-oxygenated condi-
tions, but was higher in the hypoxic perfusions, as has been
previously reported [23].
Figure 2a demonstrates that an inverse relationship exists
between perfusate pAO2 and EPO mRNA accumulation in the
perfused kidneys. EPO mRNA levels in the contralateral,
non-perfused kidneys were 0.10 0.03 X l0 (mean 1 SD),
a value similar to that obtained from kidneys of normal rats,
showing that EPO production was not stimulated during anes-
thesia and surgery. In the two control experiments performed at
a perfusate pAO2 of greater than 300 mm Hg, EPO mRNA
levels were both slightly less than in the corresponding contra-
lateral kidneys (0.06 x iO vs. 0.12 x l0, and 0.06 x l0
vs. 0.09 x io respectively). In comparison, at the lowest
perfusate pAO2 of 25 mm Hg, the EPO mRNA level was 30-fold
higher, being 1.89 x i03. After logarithmic transformation of
EPO mRNA levels, a linear relationship was present between
log (EPO mRNA) and perfusate pAO2 (Fig. 2b).
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Functional parameters in experimental groups
Table 2 shows the functional parameters of perfused kidneys
in the experimental groups. Administration of dbcAMP did not
have any significant hemodynamic effect on the perfused kid-
neys, while salbutamol, forskolin and NECA caused mild
vasodilatation. Glomerular filtration rates in all four experimen-
tal groups were similar to those in controls. In each group, renal
oxygen consumption, measured 15 minutes and 75 minutes after
administration of the agent, was not significantly different from
the level obtained before the agent was applied.
0
0
0
Table 2. Effect of administration of dbcAMP, forskolin, NECA and
salbutamol on functional parameters in perfused kidneys
Oxygen consumptio&' (molImin/g)
GFR Before agent 15 minutes 75 minutes
(mi/mm) added after after
dbcAMP 0.5 0.3 5,4 0.7 5.3 1.0 6.1 0.6
Forskolin 0.5 0.4 4.5 0.8 4.3 0.7 4.5 1.3
NECA 0.6 0.2 4.8 0.4 4.4 0.3 5.0 0.6
Salbutamol 0.4 0.2 4.9 1.2 4.3 0.7 4.1 0.5
0
0
00 00
a Symbols are: Mean 1 so of measurements at 30, 60, 90 and 115
minutes of perfusion. Results are not significantly different from control
perfusions,b Mean 1 5D of measurements at 15 minutes of perfusion, before
administration of agent, and 15 minutes and 75 minutes after. No
significant change in 02 consumption was observed.
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Fig. 2. Relationship between EPO mRNA and perfusate PO2 in control
perfusions. Isolated kidneys were perfused for 2 hours with erythro-
cyte-supplemented medium. (A) EPO mRNA, measured by RNase
protection, was inversely related to perfusate P°2, and was increased
30-fold over baseline levels at the most severe degree of hypoxia. EPO
mRNA level refers to the relative abundance of EPO mRNA to actin
mRNA. (B) After logarithmic transformation of the EPO mRNA values,
a linear relationship was present between log (EPO mRNA) and
perfusate P°2'
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Fig. 3. Autoradio graph of an RNase protection assay of EPO and
actin mRNA in isolated perfused kidneys. Control kidneys perfused
under conditions of decreasing oxygen availability showed a substantial
increase in the EPO rnRNA signal, while the actin mRNA signals,
which served as internal controls, remained unchanged. Forskolin
administered to kidneys perfused at high and low perfusate P°2
respectively, did not cause any increase in the EPO mRNA signal,
relative to actin mRNA. For each sample, the quantities of total RNA
hybridized with the EPO and actin probes were 250 g and 250 ng
respectively. The bands present below the protected EPO mRNA
fragment in Lane 2 arise from a minor degree of RNA degradation.
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Administration of dbcAMP, forskolin, NECA and salbutamol
did not result in any striking increase in EPO mRNA levels in
perfused kidneys over a range of perfusate pAO2. Figure 3
illustrates an example of an RNase protection assay of EPO
mRNA and actin mRNA in control perfused kidneys and in
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mRNA levels obtained for each agent at different degrees of
oxygen availability, plotted together with the data from control
perfusions, and demonstrates that none of the agents had a
significant stimulatory effect on EPO production. For statistical
comparison of experimental and control groups, the EPO
mRNA values, on the y-axis, were logarithmically transformed
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Fig. 4. Effects of administration of dbcAMP,forskolin, NECA and salbutamol on EPO mRNA production in isolated perfused kidneys. DbcAMP
(100 jsM), forskolin (10 sM), NECA (1 sM) and salbutamol (500 sg/liter) were each administered to a series of isolated kidneys perfused over a
range of perfusate p02, and under identical conditions as the control group. None of the agents produced a significant augmentation of EPO mRNA
levels at any of the varying conditions of oxygenation tested. The EPO mRNA level refers to the relative abundance of EPO mRNA to actin
mRNA. Solid symbols represent data from the experimental group while open symbols represent data from control perfusions.
Experiments with dbcAMP, forskolin, NECA and salbutamol perfused kidneys exposed to forskolin. Figure 4 shows the EPO
.
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Table 3. Regression coefficients and intercepts for log (Epo mRNA)
vs. perfusate P°2 for controls and experimental groups treated with
dbcAMP, forskolin, NECA and salbutamol
Intercept
Mean SD
Regression coefficient
Mean SD
dbcAMP —3.15 0.39 —1.56 >( 1O 1.13 >< lO-
Forskolin —2.81 0.13 —2.76 x lO 3.80 x 1O
NECA —3.13 0.23 —2.83 x lO 5.75 x lO
Salbutamol —2.80 0.27 —2.91 x 1O 7.07 )< lO
Controls —3.03 0,28 —3.01 x lO 6.15 >< l0—
to allow analysis by linear regression. The mean and standard
deviation of the regression coefficient for each group are shown
in Table 3. There was no statistically significant difference
between the regression coefficients of any of the experimental
groups when compared with controls.
Discussion
To determine whether the cAMP system is an important
mediator of the rapid, oxygen-dependent changes in EPO
mRNA levels, we have applied four different substances to
kidneys perfused under conditions in which oxygen-dependent
modulation of EPO mRNA was observed. The four compounds
affect the cAMP system in different ways, and have all been
reported to increase EPO production in doses equivalent to
those used in these experiments [8, 9, 10, 12, 19]. NECA, an
adenosine A2 receptor agonist [24], and salbutamol, a /32-
adrenergic agonist [25], operate through receptor-mediated
activation of adenylate cyclase. Forskolin activates adenylate
cyclase directly, by a receptor-independent mechanism 1261,
and dbcAMP is an analogue of cAMP which is operative when
exogenously applied [18].
In kidneys perfused with a perfusate hematocrit of approxi-
mately 10% and p02 in the range of 400—500 mm Hg, EPO
mRNA levels after two hours of perfusion were similar to or
slightly less than values obtained for the contralateral control
kidneys. None of the four compounds tested produced any
increase in EPO mRNA under these conditions. Control kid-
neys perfused at reduced pAO2, but under otherwise identical
conditions, had elevated levels of EPO mRNA of up to 30-fold
above baseline, the relationship between EPO mRNA and p02
being approximately logarithmic. When each of the four test
agents was added to perfusions performed over this range of
perfusate p02, no significant alteration in the regression of log
(EPO mRNA) on perfusate p02 could be discerned.
We cannot exclude the possibility of a small effect of these
compounds on modulation of EPO mRNA levels, but our
results do not support the view that cAMP is a central compo-
nent of the system mediating the rapid oxygenregulated
changes in EPO mRNA. Two other possibilities are not ex-
cluded by our experiments. Firstly, cAMP could exert an effect
on translation of EPO mRNA. Several studies have demon-
strated that alterations in EPO hormone production parallel
changes in EPO mRNA, indicating that the major control is
through modulation of mRNA levels [1, 27], These studies,
however, do not exclude the possibility that changes in trans-
lational efficiency may occur. Measurements of translational
efficiency are very difficult to make in isolated kidneys because
of the short physiological life of the perfused kidney, with the
consequent possibility of confounding effects arising from non-
specific hormone release due to deterioration of the preparation
during prolonged perfusion. Nevertheless, a recent report using
a well preserved kidney perfusion preparation did not demon-
strate an increase in overall EPO hormone production in
kidneys perfused with 10 fLM forskolin for three hours under
both well-oxygenated and hypoxic conditions [13]. A second
possibility which we cannot exclude is that cAMP might have a
modulatory effect on the regulation of EPO production which
requires prolonged stimulation, or a substantial time interval for
development.
Although these possibilities cannot be addressed in this
system, the measurement of EPO mRNA during short-term
isolated kidney perfusion has demonstrated that high ampli-
tude, oxygen-regulated changes in EPO mRNA which resemble
those observed in vivo, can be produced, and that these rapid
changes cannot be mimicked or substantially modulated by
exposure to agents which stimulate cAMP production.
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